NCT00473135View on ClinicalTrials.gov

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2010

Conditions
Dengue
Interventions
BIOLOGICAL

rDEN1delta30

Live attenuated rDEN1delta30 vaccine at a dose of 10\^3 PFU

BIOLOGICAL

Placebo

Placebo for rDEN1delta30

Trial Locations (1)

21205

Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00473135 - Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine | Biotech Hunter | Biotech Hunter